HCM
AST

Highbridge Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Highbridge Capital Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-35,555
Closed -$151K – 1850
2016
Q3 		$151K Buy
+35,555
New +$115K ﹤0.01% 1221
2015
Q3 		– Sell
-17,105
Closed -$79K – 2068
2015
Q2 		$79K Buy
+17,105
New +$164K ﹤0.01% 1344

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Highbridge Capital Management's AST Position: Q4 2016 in Review

Highbridge Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2016, closing a stake of 35,555 shares — an estimated $151K sold.

Highbridge Capital Management first reported a position in AST in Q2 2015 and held it in 2 quarters. The position peaked at $151K in Q3 2016. 66 funds tracked by Wall St. Rank hold AST as of Q4 2016.

  • Highbridge Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 35,555 Asterias Biotherapeutics Inc. Series A shares in Q4 2016, an estimated $151K.
  • Highbridge Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 2 quarters.
  • Highbridge Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $151K in Q3 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.